GroPep, an Australian company, was just granted the European patent for their drug PV903. From the press release: "GroPep is currently conducting a phase I clinical trial on PV903 to evaluate the safety and tolerability of vaginally administered PV903 gel and to determine whether PV903 has effects on vaginal immune cells in a manner consistent with its proposed role in treating immune-based infertility. Results from the trial are expected during the second half of 2006 and if successful, GroPep will seek to partner PV903 with an international pharmaceutical or biotechnology company with an established franchise in reproductive medicine. "
Recurrent miscarriage is defined as the loss of three or more consecutive pregnancies before reaching 20 weeks of gestation. GroPep states that "It is estimated that some 50% of all cases of recurrent miscarriage are the result of an inappropriate maternal immune response that treats the fetus as “foreign” and ultimately results in pregnancy loss. " Their site also elaborates on the scientific background of PV903. Personally, I would have liked to have seen references to medical articles, but they do mention the university at which the research was done.
In brief, research showed that an immune response can occur prior to conception, this response later causes diminished placental growth, immune rejection of the fetus and miscarriage.
If the clinical studies work out the way they would like them to, PV903 will be administered vaginally after intercourse. The drug will alter the female immune system and allow a strong and healthy pregnancy to occur.